News

Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study. The FDA’s Fast Track

No Serious Adverse Events (SAEs) were observed in the study. Galmed’s Chief Medical Officer, Dr. Maya Halperin stated, "The completion of the analysis adds important data to the

The safety results were consistent with the well-characterized safety profile of fingolimod in relapsing MS (RMS). PPMS is a disorder of the central nervous system (CNS) which affects

The EMA guidance is consistent with the positive feedback the Company received from the US FDA relative to the scope, design and endpoints of the program and the

The goal for a priority review is six months, for a target action date of 30 March 2015, as per the Prescription Drug User Fee Act (PDUFA). In

Conducted in collaboration with the Blood Cancer Research Partnership and Dana-Farber Cancer Institute (DFCI), the trial is designed to evaluate the safety and efficacy of the combination of

Antibody-Targeted Tumor Cell Killing 20 (ATTCK20) is a combination of a patient’s antibody-coupled T-cell receptor (ACTR) T-cells administered with rituximab, a monoclonal antibody targeting CD20. ACTR is a

Under the deal, Pfizer acquired a portion of Baxter’s facility in Orth, Austria, which manufactures meningitis vaccine, NeisVac-C as well as the encephalitis vaccine, FSME-IMMUN/TicoVac. NeisVac-C is a

Around 1,500 patients in 15 countries will be enrolled in the trial which is designed to evaluate the safety and efficacy of AZD3293/LY3314814 compared with placebo in the